Also known as MRTX849 and Krazati.
Phase III Krascendo 1: divarasib reduced risk of progression/death by 42% and risk of death by 44%; median OS ~17.7 vs 12.0 months; ORR 58% vs 32%; manageable safety.
Late‑stage results show divarasib superiority in KRAS G12C NSCLC, giredestrant preserves quality of life while improving efficacy, and Tam‑Peli shows robust activity in nasopharyngeal carcinoma.
Head‑to‑head phase III in previously treated KRAS G12C NSCLC: divarasib improved progression‑free and overall survival versus sotorasib/adagrasib with a consistent safety profile.
Head-to-head Phase III shows divarasib improves progression-free and overall survival versus sotorasib/adagrasib; safety consistent; data to be filed and presented.
